In October 2013 Optimer Pharmaceuticals (NASDAQ:OPTR) was acquired by Cubist - itself havingbeen an SBIR Awardee when it was an early-stage start-up. , A biopharmaceutical company, Optimer Pharmaceuticals, Inc had focused on discovering, developing, and commercializing anti-infective products for treatment of serious infections. The deal was for cash and Optimer ceased trading on that day. Focused on discovering, developing, and commercializing innovative hospital specialty products in diseases of unmet needs and where current therapeutic options have limitations, current development efforts address products that treat gastrointestinal infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. With an early interest in anti-biotices, the firm subsequently licensed out those technologies to others -late-stage anti-infective product candidates, Fidaxomicin and PruvelTM (prulifloxacin). Optimer Pharmaceuticals, Inc. (Optimer) focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
